OMEGALIFE-3™

OMEGALIFE-3™
Omega-3 Fatty Acid Supplementation

DESCRIPTION
OmegaLife-3™ is a blend of omega-3 fatty acids designed to help maintain healthy cardiovascular and cerebral function.
OmegaLife-3™ is an amber-colored, semi-viscous, fat-soluble liquid. Each serving of OmegaLife-3™ contains the following active ingredients: 800 mg eicosapentaenoic acid (EPA), 400 mg docosahexaenoic acid (DHA), and vitamin E. In addition, it also contains the inactive ingredients gelatin, glycerin, purified water, and orange oil. OmegaLife-3™ has been molecularly distilled to ensure exceptionally pure oil and includes orange oil to prevent a fishy aftertaste.


BENEFITS AND RESEARCH
Clinical research suggests fish oil can help support proper brain and visual function. In 2002 the FDA approved supplementation of DHA in infant formula. DHA is potentially important in fetal and infant neural development, in that DHA and arachidonic acid have been shown to be incorporated into brain and retinal cell membranes—particularly during the third trimester of pregnancy and early infant life.
DHA is the predominant structural fatty acid in the central nervous system and in the retina of the eyes.
EPA supports the synthesis of important compounds in the body. EPA is the precursor of thromboxane and leukotriene, compounds involved in supporting healthy circulation. They also promote healthy blood vessels.
Evidence is accumulating that increasing intakes of EPA and DHA can decrease the risk thrombosis, decrease triglyceride levels, and decrease inflammation.1
The U.S. Food and Drug Administration (FDA) has stated, “Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease.”

USAGE
Take two softgels twice daily with a meal.

SAFETY AND WARNINGS
OmegaLife-3™ is well tolerated. As with any dietary supplement, some gastrointestinal discomfort may be experienced. Common side effects include a “fishy” taste upon eructation.

HOW SUPPLIED
Available in softgels.

REFERENCES
Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol. 2008 Oct 15:102(8):1040-5
Lee JH, Harris WS, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008 Mar;83(3):324-32.
SanGiovanni JP, Chew EY, Sperduto RD, et al. The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch Ophthalmol. 2008 Sep;126(9):1274-9.
SanGiovanni JP, Parra-Cabrera S, Colditz GA, Berkey CS, Dwyer JT. Meta-analysis of dietary essential fatty acids and long-chain polyunsaturated fatty acids as they relate to visual resolution acuity in healthy preterm infants. Pediatrics 2000;105:1292-8.
Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23(2):151-152.
1THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.